Thursday, March 30, 2023 6:25:28 PM
From my original email posted here in which i voiced my disappointment with Revive management...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171514727
His reply was that i should speak to and argue with the FDA because they're the governing body. He gave examples of other companies that had difficulties trying to get through to the FDA. And, shareholders knew the risks.
I responded with "A poorly designed clinical trial is not the FDA’s fault, the fault falls on Revive’s management."
In reply MF stated that the trial was designed with hospitalization and the environment changed.
In response i stated that for shareholder's sake i hope Revive has a good plan for moving forward.
His reply was for me to read the Press Releases.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM